

20 November 2006

To all Pharmaceutical Suppliers, Hospital Pharmacists, Medical Groups and Interested Parties www.pharmac.govt.nz

Consultation on a proposal relating to mometasone furoate, infliximab and eptifibatide

PHARMAC has entered into a provisional agreement with Schering-Plough Animal Health Limited in relation to the pharmaceuticals mometasone furoate (Elocon), infliximab (Remicade) and eptifibatide (Integrilin). Details of the proposals are as below:

- Mometasone furoate would continue to be listed in Section B of the Pharmaceutical Schedule at the current prices and subsidies as follows:

Presentation	Strength	Brand	Price and Subsidy	Pack Size
Ointment	0.1%	Elocon	\$3.96	15 g OP
Ointment	0.1%	Elocon	\$10.82	45 g OP
Cream	0.1%	Elocon	\$3.96	15 g OP
Cream	0.1%	Elocon	\$10.82	45 g OP
Lotion	0.1%	Elocon	\$4.80	30 ml OP

Prices and subsidies are ex-manufacturer, ex-GST.

- The following pharmaceuticals would be listed in Part II of Section H of the Pharmaceutical Schedule at the following prices:

Chemical	Presentation	Strength	Brand	Price	Pack Size
Mometasone furoate	Ointment	0.1%	Elocon	\$3.96	15 g OP
Mometasone furoate	Ointment	0.1%	Elocon	\$10.82	45 g OP
Mometasone furoate	Cream	0.1%	Elocon	\$3.96	15 g OP
Mometasone furoate	Cream	0.1%	Elocon	\$10.82	45 g OP
Mometasone furoate	Lotion	0.1%	Elocon	\$4.80	30 ml OP
Infliximab	Powder for injection	100 mg	Remicade	\$1,227.00	1
Eptifibatide	Injection	2 mg per ml, 10 ml	Integrilin	\$111.00	1
Eptifibatide	Injection	0.75 mg per ml, 100 ml	Integrilin	\$324.00	1

Prices and subsidies are ex-manufacturer, ex-GST.

- Elocon would be subject to a confidential rebate.
- Elocon would have subsidy protection in Section B of the Pharmaceutical Schedule until 31 January 2009.

It is anticipated that the proposed changes, if approved by PHARMAC's Board, would take effect from 1 February 2007. If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to Stephen Woodruffe at PHARMAC by 5:00 pm, 1 December 2006.

Yours sincerely



Stephen Woodruffe
Therapeutic Group Manager